NAS:HZNP (Ireland) Also trade in: Germany

Horizon Therapeutics PLC

$ 24.46 -1.11 (-4.34%)
Volume: 1,024,743 Avg Vol (1m): 1,993,715
Market Cap $: 4.55 Bil Enterprise Value $: 5.12 Bil
P/E (TTM): 94.70 P/B: 2.83
Earnings Power Value 1.08
Net Current Asset Value -5.05
Tangible Book -4.64
Projected FCF 21.94
Median P/S Value 27.35
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.65
Cash-To-Debt ranked lower than
74.27% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
HZNP: 0.65
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.07, Med: 0.6, Max: 2.56
Current: 0.65
0.07
2.56
Equity-to-Asset 0.38
Equity-to-Asset ranked lower than
91.50% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
HZNP: 0.38
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.77, Med: 0.42, Max: 0.7
Current: 0.38
-0.77
0.7
Debt-to-Equity 1.07
Debt-to-Equity ranked lower than
95.81% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
HZNP: 1.07
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -2.51, Med: 0.84, Max: 2.21
Current: 1.07
-2.51
2.21
Debt-to-EBITDA 4.35
Debt-to-EBITDA ranked lower than
97.78% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
HZNP: 4.35
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -24.41, Med: -0.42, Max: 13.54
Current: 4.35
-24.41
13.54
Interest Coverage 0.82
Interest Coverage ranked lower than
100.00% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
HZNP: 0.82
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.08, Med: 0.44, Max: 0.82
Current: 0.82
0.08
0.82
Piotroski F-Score 8
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.37
DISTRESS
GREY
SAFE
Beneish M-Score -2.92
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 64.22%
WACC 6.99%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 7.73
Operating Margin ranked lower than
76.40% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
HZNP: 7.73
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1841.5, Med: -34.19, Max: 7.73
Current: 7.73
-1841.5
7.73
Net Margin % 3.98
Net Margin ranked lower than
77.93% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
HZNP: 3.98
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1635.12, Med: -88.77, Max: 5.22
Current: 3.98
-1635.12
5.22
ROE % 4.84
ROE ranked lower than
78.73% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
HZNP: 4.84
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -523.78, Med: -57.66, Max: 4.84
Current: 4.84
-523.78
4.84
ROA % 1.25
ROA ranked lower than
69.80% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
HZNP: 1.25
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -176.97, Med: -35.22, Max: 1.89
Current: 1.25
-176.97
1.89
ROC (Joel Greenblatt) % 506.64
ROC (Joel Greenblatt) ranked lower than
90.64% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
HZNP: 506.64
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -3463.41, Med: -1393.9, Max: 520.88
Current: 506.64
-3463.41
520.88
3-Year Total Revenue Growth Rate 16.80
3-Year Revenue Growth Rate ranked higher than
86.65% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
HZNP: 14.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 18.3, Max: 115.5
Current: 14.4
0
115.5
3-Year Total EBITDA Growth Rate 13.80
3-Year EBITDA Growth Rate ranked lower than
100.00% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
HZNP: 11.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 5.75, Max: 73.2
Current: 11.5
0
73.2

» HZNP's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:HZNP

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare BOM:532321 SHSE:600535 SZSE:000423 OHEL:ORNAV SZSE:300601 NAS:TLRY TSE:4516 LSE:HIK SHSE:600566 BSP:HYPE3 NYSE:TARO SHSE:603858 BOM:500257 SZSE:002773 TSX:CRON SZSE:000999 NYSE:AMRX BUD:RICHTER SHSE:600277 XTER:EVT
Traded in other countries HPR.Germany
Address 1 Burlington Road, Connaught House, 1st Floor, Dublin 4, IRL, D04 C5Y6
Horizon Pharma is a specialty and generic drug manufacturing company. The company is focused on the identification, development, acquisition, and commercialization of differentiated and accessible medicines that address unmet medical needs. The overwhelming majority of revenue is generated in the United States. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ratios

Current vs industry vs history
PE Ratio (TTM) 94.70
PE Ratio ranked lower than
100.00% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
HZNP: 94.7
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 81.05, Med: 103.21, Max: 208.89
Current: 94.7
81.05
208.89
Forward PE Ratio 16.18
Forward P/E ranked higher than
76.58% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
HZNP: 16.18
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 94.70
PE without NRI ranked lower than
100.00% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
HZNP: 94.7
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 81.05, Med: 103.21, Max: 208.89
Current: 94.7
81.05
208.89
Price-to-Owner-Earnings 31.02
Price-to-Owner-Earnings ranked lower than
100.00% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
HZNP: 31.02
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 15.02, Med: 24.34, Max: 35.49
Current: 31.02
15.02
35.49
PB Ratio 2.83
PB Ratio ranked lower than
68.25% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
HZNP: 2.83
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.8, Med: 2.35, Max: 14.94
Current: 2.83
0.8
14.94
PS Ratio 3.29
PS Ratio ranked lower than
51.61% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
HZNP: 3.29
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.47, Med: 3.66, Max: 19
Current: 3.29
1.47
19
Price-to-Free-Cash-Flow 13.61
Price-to-Free-Cash-Flow ranked higher than
73.83% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
HZNP: 13.61
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 4.96, Med: 12.69, Max: 433
Current: 13.61
4.96
433
Price-to-Operating-Cash-Flow 13.34
Price-to-Operating-Cash-Flow ranked higher than
64.29% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
HZNP: 13.34
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.84, Med: 11.71, Max: 209.52
Current: 13.34
4.84
209.52
EV-to-EBIT 52.41
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
HZNP: 52.41
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -775.4, Med: -4.4, Max: 302.9
Current: 52.41
-775.4
302.9
EV-to-EBITDA 13.83
EV-to-EBITDA ranked lower than
89.95% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
HZNP: 13.83
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -608, Med: -0.6, Max: 518
Current: 13.83
-608
518
EV-to-Revenue 4.02
EV-to-Revenue ranked lower than
59.37% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
HZNP: 4.02
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.5, Med: 4.4, Max: 30.2
Current: 4.02
0.5
30.2
Current Ratio 1.74
Current Ratio ranked lower than
65.38% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
HZNP: 1.74
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.16, Med: 1.74, Max: 4.39
Current: 1.74
0.16
4.39
Quick Ratio 1.68
Quick Ratio ranked lower than
55.56% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
HZNP: 1.68
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.16, Med: 1.62, Max: 4.27
Current: 1.68
0.16
4.27
Days Inventory 52.38
Days Inventory ranked higher than
81.06% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
HZNP: 52.38
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 13.1, Med: 71.61, Max: 201.46
Current: 52.38
13.1
201.46
Days Sales Outstanding 116.62
Days Sales Outstanding ranked lower than
81.56% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
HZNP: 116.62
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 67.08, Med: 101.46, Max: 140.47
Current: 116.62
67.08
140.47
Days Payable 33.74
Days Payable ranked lower than
89.97% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
HZNP: 33.74
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 23.56, Med: 97.38, Max: 410.36
Current: 33.74
23.56
410.36

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.60
3-Year Share Buyback Rate ranked lower than
61.30% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
HZNP: -1.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -428.1, Med: -61.1, Max: -1.6
Current: -1.6
-428.1
-1.6

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.12
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
68.98% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
HZNP: 1.12
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.93, Med: 1.32, Max: 29.51
Current: 1.12
0.93
29.51
Price-to-Median-PS-Value 0.90
Price-to-Median-PS-Value ranked higher than
59.22% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
HZNP: 0.9
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.48, Med: 0.97, Max: 4.63
Current: 0.9
0.48
4.63
Earnings Yield (Joel Greenblatt) % 1.87
Earnings Yield (Greenblatt) ranked lower than
75.20% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
HZNP: 1.87
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -913.1, Med: -4.1, Max: 2.6
Current: 1.87
-913.1
2.6

More Statistics

Revenue (TTM) (Mil) $ 1,264.06
EPS (TTM) $ 0.26
Beta 1.19
Volatility % 47.86
52-Week Range $ 14.89 - 29.44
Shares Outstanding (Mil) 184.88

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 8
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y